ARCH THERAPEUTICS

Codice
Arth
Risorse esterne
Opinione della community
Prezzo Variazione Volume
0.68 +1.49 €
(+-183.95%)
235074
P/E Obiettivo ad 1anno
0 2.53 €

Compra - Vendi

0
Tutte le tue transazioni per questo titolo

Devi effettuare l'accesso


Grafico

Altri utenti che hanno investito

Transations in last week
Buy: 14
Sell : 4

Sebastiano Salemi Simone Bonzanini Cerbero

Commenti


Notizie

ARCH THERAPEUTICS, INC. (OTCMKTS:ARTH) Files An 8-K Entry into a Material Definitive Agreement - Market Exclusive

Arch Therapeutics, Inc. is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care.altro » Leggi

Arch Therapeutics Inc (ARTH) stock starts with “Buy” rating in note to investors by Rodman & Renshaw - The Ledger Gazette

Arch Therapeutics Inc (NASDAQ: ARTH) shares rose on Monday February 13 on lower trade volume than normal after more analysts initiated coverage on the stock. Meanwhile U.S. stock-market indexes opened higher on Monday, setting intraday all-time ... Leggi

The Arch Therapeutics Inc (ARTH) Stock Rating Reaffirmed by Roth Capital - DailyQuint

Arch Therapeutics Inc (OTC:ARTH)'s stock had its “buy” rating reiterated by stock analysts at Roth Capital in a note issued to investors on Monday. Arch Therapeutics (OTC:ARTH) traded down 0.6374% during mid-day trading on Monday, hitting $0.7015. Leggi

Arch Therapeutics Inc (ARTH) Now Covered by Roth Capital - Chaffey Breeze

Arch Therapeutics (NASDAQ:ARTH) traded up 1.885% during mid-day trading on Tuesday, hitting $0.706. 609,279 shares of the company's stock were exchanged. Arch Therapeutics has a 12 month low of $0.18 and a 12 month high of $0.95. The stock's 50 ... Leggi

A statement released earlier today by Roth Capital about Arch Therapeutics Inc (NASDAQ:ARTH) bumps the target ... - Breaking Finance News

Previously on 2/13/2017, Rodman & Renshaw reported about Arch Therapeutics Inc (NASDAQ:ARTH) raised the target price from $0.00 to $2.50. At the time, this indicated a possible upside of 2.85%. Yesterday Arch Therapeutics Inc (NASDAQ:ARTH) traded ... Leggi

Steady Progress at Arch Therapeutics Inc (OTCMKTS:ARTH) - The Oracle Dispatch

Arch Therapeutics Inc (OTCMKTS:ARTH) is a low-priced trading equity that has spent a lot of time this year front and center on the radar for most OTC traders. That has particularly been the case in recent days as the Company has taken to the road to ... Leggi

A Market Overreaction On Arch Therapeutics Inc (OTCBB:ARTH) - Insider Financial

The market has overreacted by quite a bit on Arch Therapeutics Inc (OTCBB:ARTH) after the latest SEC filing. Shares dropped more than 25% ... For the first part of this year, ARTH traded primarily between $.175 and $.20 per share. An equity raise at ...altro » Leggi

Arch Therapeutics Inc (OTCMKTS:ARTH): Stopping Bleeding In Record Time - Insider Financial

Arch Therapeutics Inc (OTCMKTS:ARTH) is a stock we profiled a little over two months ago after it had sunk more than 25%, as information was released as to the filing of a prospectus with the SEC. The article focused on what we believed to be an ... Leggi

Arch Therapeutics AC5 Topical Hemostatic Device effective in patients on antiplatelet medication; shares up 8% - Seeking Alpha

Thinly traded nano cap Arch Therapeutics (OTCQB:ARTH +8.2%) moves up on a 50% surge in volume in response to its announcement of additional positive data from a previously reported study assessing its AC5 Topical Hemostatic Device in skin lesion ...altro » Leggi

Arch Therapeutics Seals The Deal On Strong Trial Data For Its AC5 Hemostatic Device - Seeking Alpha

Arch Therapeutics (OTCQB:ARTH) reported on August 15, 2016 the results from its first "in human" trial of its AC5 Topical Hemostatic Device. The company reported that the study met both its primary and secondary endpoints, with a statistically ...altro » Leggi